# Chemours share price today (The Chemours Company, CC)

> The Chemours Company's share price has risen faster than its earnings: −2.2% in a year, against −658.7% for earnings per share. CC · Materials · Specialty Chemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/cc

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $13.09 (−2.2% in a year)
- P/E: 234.9× (higher than 92% of the last 3.6 years)
- Revenue (Jun 2026): $1.6 B (−1.5% on a year ago)
- Profit (Jun 2026): −$274 M
- Operating margin: 1.1% (−6.4 points on a year ago)
- ROE: −154%, FY25
- ROIC: −5.7%, against a −1.4% cost of capital: −4.3 points
- Profit that came in as cash: 75%, last 3 years

The main question: the share price moved −2.2% in a year while yearly earnings per share moved −658.7%. The difference came from the market paying a higher multiple. ## What is the Chemours share price today? The Chemours Company's share price was $13.09 at the close on 3 November 2026. It has been moving sideways for 17 weeks. That is 28.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $11 and $28, and at that close it sat 12% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 20 weeks running. Over the last 10 years the share price moved +70% while the S&P 500 moved +255%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Chemours pay? The Chemours Company paid $0.35 per share over the last four reported quarters. The most recent declaration was $0.09 for Jun 2026. At today's price of $13.09 that is a yield of 2.67%, based on dividends already paid, not a forecast. ## Which stock lists is Chemours on? Chemours is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Chemours profitable? The Chemours Company posted a net loss of $274 M in the Jun 2026 quarter. The full FY25 year was a loss of $386 M. That loss is 17.2% of the quarter's revenue. The same quarter a year earlier lost $380 M. 8 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was −$386 M (−659.4% on the year before). ## How much revenue does Chemours make, and is it growing? The Chemours Company reported $1.6 B of revenue in the Jun 2026 quarter, −1.5% on the same quarter a year earlier. Over 4 years it has grown −2.2% a year on average. The last full year, FY25, came in at $5.8 B. The last four reported quarters add to $5.8 B. FY25 revenue was $5.8 B, +0.4% on the year before. Recent pace: the last four quarters grew −0.9% on average, against −2.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −0.9%, against −0.2% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Chemours keep? The Chemours Company's operating margin was 1.1% in the Jun 2026 quarter, 6.4 percentage points lower than the same quarter a year ago. Across 5 years it has been between −0.9% and 11.6%. The latest quarter is within that range. Why the margin moved: operating margin changed −6.4 percentage points on the year while gross margin changed +0.8 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Chemours' profit turning into cash? Over the last 3 years, 75% of The Chemours Company's reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in $264 M of operating cash against −$386 M of profit. After $213 M of spending on assets, $51.0 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Chemours' cash go? The Chemours Company does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $943 M on assets over the last 3 years. Averaged over those years that is 5.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $943 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Chemours' P/E ratio, and how does it compare with its own history? The Chemours Company's P/E is 234.9×, near the high end of its own history: higher than 92% of past readings. Its usual P/E (the middle reading) is 11.2×, over 3.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −658.7% while the price moved −2.2%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved −20.1% a year; about −78.3% a year came from earnings growth and about +58.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Chemours business getting better or worse? The Chemours Company's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Chemours earn on its capital? The Chemours Company earned a ROE of −154% in FY25. Its return on capital used (ROIC) is 4.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −6.6% net margin and 0.79× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −6.6% net margin × 0.79× asset turnover × 29.41× leverage (assets divided by equity) ≈ −153.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −5.7% − −1.4% = −4.3 percentage points. The −1.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −5.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 7.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Chemours have too much debt? The Chemours Company's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 3.68 in FY21 to 17.51 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Chemours shareholding pattern? 9.9% of The Chemours Company's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 7.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Chemours from balance-sheet trouble? For The Chemours Company, the Z-score is 1.56. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.56 is inside the danger zone, so the balance sheet is a real risk. ## How does Chemours rank in its industry? There is no score against its industry: The Chemours Company is not among the largest members shown in this industry comparison for Specialty Chemicals. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Chemours compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Chemours in size? Chemours is the 33rd largest of 47 Specialty Chemicals companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Ingevity Corporation, Innospec Inc. and Minerals Technologies Inc. Just below it: Stepan Company, Ecovyst Inc. and Oil-Dri Corporation of America. ### Specialty Chemicals companies close in size

1. [Ingevity Corporation](https://www.sectoralpha.in/us/stocks/ngvt) $2.5 billion
2. [Innospec Inc.](https://www.sectoralpha.in/us/stocks/iosp) $2.4 billion
3. [Minerals Technologies Inc.](https://www.sectoralpha.in/us/stocks/mtx) $2 billion
4. The Chemours Company $2 billion
5. [Stepan Company](https://www.sectoralpha.in/us/stocks/scl) $1.6 billion
6. [Ecovyst Inc.](https://www.sectoralpha.in/us/stocks/ecvt) $1.1 billion
7. [Oil-Dri Corporation of America](https://www.sectoralpha.in/us/stocks/odc) $1 billion

[All 47 Specialty Chemicals companies, largest first](https://www.sectoralpha.in/us/sectors/specialty-chemicals#all-companies)

### Companies close in size in other industries

1. [Sunrun Inc.](https://www.sectoralpha.in/us/stocks/run) $2 billion · Solar
2. [BlackLine, Inc.](https://www.sectoralpha.in/us/stocks/bl) $2 billion · Software - Application
3. The Chemours Company $2 billion
4. [ChipMOS TECHNOLOGIES INC.](https://www.sectoralpha.in/us/stocks/imos) $2 billion · Semiconductors
5. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) $2 billion · Medical Instruments & Supplies

## What else do people ask about Chemours? ### What is Chemours's stock price today? The Chemours Company's stock price is $13.09, −2.2% over the past year. The whole company is worth $2.0 B on the market. In the last 52 weeks it traded between $11 to $28; today it is 12% of the way up from the low, 28.8% below its 200-day average (as of 3 November 2026). ### What were Chemours's latest quarterly results? The Chemours Company reported revenue of $1.6 B and a net loss of $274 M for the Jun 2026 quarter. Earnings per share were −$1.81. The operating margin was 1.1%, 6.4 percentage points lower than a year earlier (as of 3 November 2026). ### What is Chemours's market cap? The Chemours Company's market capitalisation is $2.0 B at a stock price of $13.09. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Chemours performing? The Chemours Company's share price has been moving sideways for 17 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 20 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Chemours's stock price go up? This page does not forecast The Chemours Company's stock price. What it shows instead: the stock price is $13.09, and it has been moving sideways for 17 weeks. Its P/E of 234.9× is higher than 92% of its own last 4 years (as of 3 November 2026). ### Does Chemours have too much debt? Yes, The Chemours Company has a lot of debt: its debt is 25.80× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Chemours in its business cycle? The Chemours Company's FY25 operating margin was 5.1%, against a 5-year range of −0.9% to 11.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 1.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Chemours story? The main question: the share price moved −2.2% in a year while yearly earnings per share moved −658.7%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Chemours a stock worth studying right now? What the numbers show: The Chemours Company's share price has risen faster than its earnings: −2.2% in a year, against −658.7% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.